Company registration number 03522198 (England and Wales)
MANCHESTER PERFUSION PRACTICE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024
PAGES FOR FILING WITH REGISTRAR
MANCHESTER PERFUSION PRACTICE LIMITED
CONTENTS
Page
Company information
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 9
MANCHESTER PERFUSION PRACTICE LIMITED
COMPANY INFORMATION
- 1 -
Directors
Mr Craig Mottershead
Mr Mark Lynn
Company number
03522198
Registered office
12D Woodford Road
Bramhall
Cheshire
UK
SK7 1JJ
Accountants
Hallidays
Riverside House
Kings Reach Business Park
Yew Street
Stockport
Cheshire
SK4 2HD
MANCHESTER PERFUSION PRACTICE LIMITED
BALANCE SHEET
AS AT 30 APRIL 2024
30 April 2024
- 2 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
3
-
0
34,965
Tangible assets
4
34,729
28,380
34,729
63,345
Current assets
Stocks
5
136,418
77,212
Debtors
6
382,282
311,498
Cash at bank and in hand
74,102
75,536
592,802
464,246
Creditors: amounts falling due within one year
7
(323,899)
(272,029)
Net current assets
268,903
192,217
Total assets less current liabilities
303,632
255,562
Creditors: amounts falling due after more than one year
8
(32,344)
(37,951)
Provisions for liabilities
(4,599)
(4,496)
Net assets
266,688
213,114
Capital and reserves
Called up share capital
10
100
100
Profit and loss reserves
266,588
213,014
Total equity
266,688
213,114

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

MANCHESTER PERFUSION PRACTICE LIMITED
BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2024
30 April 2024
- 3 -
The financial statements were approved by the board of directors and authorised for issue on 22 January 2025 and are signed on its behalf by:
Mr Craig Mottershead
Mr Mark Lynn
Director
Director
Company Registration No. 03522198
MANCHESTER PERFUSION PRACTICE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024
- 4 -
1
Accounting policies
Company information

Manchester Perfusion Practice Limited is a private company limited by shares incorporated in England and Wales. The registered office is 12D Woodford Road, Bramhall, Cheshire, UK, SK7 1JJ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The financial statements have been prepared on a going concern basis.

1.3
Turnover

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

 

The company recognises revenue when:

The amount of revenue can be reliably measured;

it is probable that future economic benefits will flow to the entity;

and specific criteria have been met for each of the company's activities.

1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

 

Goodwill
10% Straight Line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

MANCHESTER PERFUSION PRACTICE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2024
1
Accounting policies
(Continued)
- 5 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
20% Reducing Balance
Fixtures, fittings & equipment
20% Reducing Balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

MANCHESTER PERFUSION PRACTICE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2024
1
Accounting policies
(Continued)
- 6 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation
Current tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Deferred tax

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

 

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

 

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

MANCHESTER PERFUSION PRACTICE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2024
- 7 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
13
13
3
Intangible fixed assets
Goodwill
£
Cost
At 1 May 2023 and 30 April 2024
460,076
Amortisation and impairment
At 1 May 2023
425,111
Amortisation charged for the year
34,965
At 30 April 2024
460,076
Carrying amount
At 30 April 2024
-
0
At 30 April 2023
34,965
4
Tangible fixed assets
Leasehold improvements
Fixtures, fittings & equipment
Total
£
£
£
Cost
At 1 May 2023
63,522
205,986
269,508
Additions
-
0
13,475
13,475
At 30 April 2024
63,522
219,461
282,983
Depreciation and impairment
At 1 May 2023
59,413
181,715
241,128
Depreciation charged in the year
822
6,304
7,126
At 30 April 2024
60,235
188,019
248,254
Carrying amount
At 30 April 2024
3,287
31,442
34,729
At 30 April 2023
4,109
24,271
28,380
MANCHESTER PERFUSION PRACTICE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2024
- 8 -
5
Stocks
2024
2023
£
£
Stocks
136,418
77,212
6
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
210,966
114,526
Other debtors
3,996
6,196
Prepayments and accrued income
167,320
190,776
382,282
311,498
7
Creditors: amounts falling due within one year
2024
2023
Notes
£
£
Bank loans
9
5,607
5,607
Trade creditors
165,894
156,905
Corporation tax
93,817
62,817
Other taxation and social security
21,268
15,153
Accruals and deferred income
37,313
31,547
323,899
272,029

 

8
Creditors: amounts falling due after more than one year
2024
2023
Notes
£
£
Bank loans and overdrafts
9
32,344
37,951
9
Loans and overdrafts
2024
2023
£
£
Bank loans
37,951
43,558
Payable within one year
5,607
5,607
Payable after one year
32,344
37,951

 

MANCHESTER PERFUSION PRACTICE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2024
9
Loans and overdrafts
(Continued)
- 9 -

 

10
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
100
100
11
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
8,747
23,928
12
Related party transactions

Perfusion Solutions Limited

 

During the year the company paid management fees of £7,278 (2023: £9,854 ) to Perfusion Solutions Limited. At the balance sheet date the amount owed from Perfusion Solutions Limited was £Nil (2023: £Nil).

13
Parent company

The ultimate controlling party is Perfusion Solutions Limited.

2024-04-302023-05-01falsefalsefalse22 January 2025CCH SoftwareCCH Accounts Production 2024.310No description of principal activityMr Craig MottersheadMr Mark Lynn035221982023-05-012024-04-3003522198bus:Director12023-05-012024-04-3003522198bus:Director22023-05-012024-04-3003522198bus:RegisteredOffice2023-05-012024-04-30035221982024-04-30035221982023-04-3003522198core:NetGoodwill2024-04-3003522198core:NetGoodwill2023-04-3003522198core:LeaseholdImprovements2024-04-3003522198core:FurnitureFittings2024-04-3003522198core:LeaseholdImprovements2023-04-3003522198core:FurnitureFittings2023-04-3003522198core:CurrentFinancialInstrumentscore:WithinOneYear2024-04-3003522198core:CurrentFinancialInstrumentscore:WithinOneYear2023-04-3003522198core:Non-currentFinancialInstrumentscore:AfterOneYear2024-04-3003522198core:Non-currentFinancialInstrumentscore:AfterOneYear2023-04-3003522198core:CurrentFinancialInstruments2024-04-3003522198core:CurrentFinancialInstruments2023-04-3003522198core:ShareCapital2024-04-3003522198core:ShareCapital2023-04-3003522198core:Goodwill2023-05-012024-04-3003522198core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-05-012024-04-3003522198core:LeaseholdImprovements2023-05-012024-04-3003522198core:FurnitureFittings2023-05-012024-04-30035221982022-05-012023-04-3003522198core:NetGoodwill2023-04-3003522198core:NetGoodwill2023-05-012024-04-3003522198core:LeaseholdImprovements2023-04-3003522198core:FurnitureFittings2023-04-30035221982023-04-3003522198core:Non-currentFinancialInstruments2024-04-3003522198core:Non-currentFinancialInstruments2023-04-3003522198bus:PrivateLimitedCompanyLtd2023-05-012024-04-3003522198bus:SmallCompaniesRegimeForAccounts2023-05-012024-04-3003522198bus:FRS1022023-05-012024-04-3003522198bus:AuditExemptWithAccountantsReport2023-05-012024-04-3003522198bus:FullAccounts2023-05-012024-04-30xbrli:purexbrli:sharesiso4217:GBP